Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2026 04:00 ET | Source: SK pharmteco Inc.

SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment

SK pharmteco reaffirms its three business unit strategy - small molecules, peptides, and viral vectors - with $100 million funding commitment.
March 17, 2026 09:03 ET | Source: SK pharmteco Inc.

SK pharmteco Announces Successful FDA Inspection of Small Molecule Manufacturing Facility in La Porte, Texas

SK pharmteco today announced the successful conclusion of a regulatory inspection of its small molecule North America facility in La Porte, Texas.
October 30, 2025 02:40 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases

Boehringer has licensed a small molecule program from Kyowa Kirin focused on developing potential treatments for autoimmune diseases.
October 23, 2025 09:30 ET | Source: SNS Insider pvt ltd

Bioanalytical Testing Services Market Size Expected to Reach USD 9.68 Billion by 2032 – SNS Insider

Austin, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Bioanalytical Testing Services Market Size & Growth Analysis: According to SNS Insider, the global Bioanalytical Testing Services Market is witnessing...
June 25, 2024 08:07 ET | Source: Cybrexa Therapeutics

Industry Leader John Maraganore, Ph.D., Joins Cybrexa Therapeutics as Strategic Advisor

NEW HAVEN, Conn., June 25, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
February 06, 2024 08:00 ET | Source: Cybrexa Therapeutics

Cybrexa Regains Rights to CBX-12

NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
August 08, 2023 04:00 ET | Source: Astex Pharmaceuticals

Astex Expands Drug Discovery Collaboration With MSD

CAMBRIDGE, United Kingdom, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals (UK) (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule...
July 25, 2023 14:33 ET | Source: Persistence Market Research

Growing Emphasis on Generic Drug Manufacturing Boosts Active Pharmaceutical Ingredient Market to US$ 300.2 Billion by 2033: Persistence Market Research

New York, July 25, 2023 (GLOBE NEWSWIRE) -- Worldwide revenue from the active pharmaceutical ingredients market stands at US$ 192.3 Billion in 2022, with the global market estimated to surge ahead...
May 25, 2023 17:01 ET | Source: Cybrexa Therapeutics

Cybrexa Therapeutics To Present Data at ASCO 2023 Highlighting First-In-Human, Dose-Finding Study of Lead Candidate CBX-12

Activity and Safety Profile Reinforces Potential of CBX-12 in Solid TumorsFour Objective Responses Observed in Breast and Ovarian Cancers with CBX-12Dose-Limiting Toxicity Identified as...
April 12, 2023 08:00 ET | Source: Cybrexa Therapeutics

Cybrexa Appoints Jaya Gautam as Senior Vice President of Technical Operations

NEW HAVEN, Conn., April 12, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...